Clinical Trial Update: A Phase 1 Study of JV-213 Autologous CD79b-targeting Chimeric Antigen Receptor T-cell Therapy in Adults With Relapsed or Refractory B-cell Lymphomas [Phase 1]

View source ↗

Summary

A Phase 1 study evaluating JV-213, an autologous CD79b-targeting CAR T-cell therapy, in adults with relapsed or refractory B-cell lymphomas; currently recruitin…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• B-cell Lymphoma
• Non-hodgkin Lymphoma

Drugs mentioned

• JV-213

Snippet

Sponsor: M.D. Anderson Cancer Center | Conditions: Lymphomas, B-cell Lymphomas | Phase 1 | Status: RECRUITING